Oxfordshire Community Stroke Project classification but not NIHSS predicts symptomatic intracerebral hemorrhage following thrombolysis

2013 ◽  
Vol 324 (1-2) ◽  
pp. 65-69 ◽  
Author(s):  
Sheng-Feng Sung ◽  
Chi-Shun Wu ◽  
Yung-Chu Hsu ◽  
Mei-Chiun Tseng ◽  
Yu-Wei Chen
BMC Neurology ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Sheng-Feng Sung ◽  
Solomon Chih-Cheng Chen ◽  
Huey-Juan Lin ◽  
Chih-Hung Chen ◽  
Mei-Chiun Tseng ◽  
...  

Neurology ◽  
2009 ◽  
Vol 72 (8) ◽  
pp. 763-765 ◽  
Author(s):  
M. W. Vernooij ◽  
J. Heeringa ◽  
G. J. de Jong ◽  
A. van der Lugt ◽  
M.M.B. Breteler

Stroke ◽  
2012 ◽  
Vol 43 (6) ◽  
pp. 1524-1531 ◽  
Author(s):  
Michael Mazya ◽  
José A. Egido ◽  
Gary A. Ford ◽  
Kennedy R. Lees ◽  
Robert Mikulik ◽  
...  

2019 ◽  
Vol 14 (7) ◽  
pp. 670-677
Author(s):  
Xia Wang ◽  
Jingwei Li ◽  
Tom J Moullaali ◽  
Keon-Joo Lee ◽  
Beom Joon Kim ◽  
...  

Objective To investigate the comparative efficacy and safety of the low-dose versus standard-dose alteplase using real-world acute stroke registry data from Asian countries. Methods Individual participant data were obtained from nine acute stroke registries from China, Japan, Philippines, Singapore, South Korea, and Taiwan between 2005 and 2018. Inverse probability of treatment weight was used to remove baseline imbalances between those receiving low-dose versus standard-dose alteplase. The primary outcome was death or disability defined by modified Rankin Scale scores of 2 to 6 at 90 days. Secondary outcomes were symptomatic intracerebral hemorrhage and death. Generalized linear mixed models with the individual registry as a random intercept were performed to determine associations of treatment with low-dose alteplase and outcomes. Results Of the 6250 patients (mean age 66 years, 36% women) included in these analyses, 1610 (24%) were treated with low-dose intravenous alteplase. Clinical outcomes for low-dose alteplase were not significantly different to those for standard-dose alteplase, adjusted odds ratios for death or disability: 1.00 (0.85–1.19) and symptomatic intracerebral hemorrhage 0.87 (0.63–1.19), except for lower death with borderline significance, 0.77 (0.59–1.01). Conclusions The present analyses of real-world Asian acute stroke registry data suggest that low-dose intravenous alteplase has overall comparable efficacy for functional recovery and greater potential safety in terms of reduced mortality, to standard-dose alteplase for the treatment of acute ischemic stroke.


Neurology ◽  
2008 ◽  
Vol 71 (17) ◽  
pp. 1304-1312 ◽  
Author(s):  
M. Saqqur ◽  
G. Tsivgoulis ◽  
C. A. Molina ◽  
A. M. Demchuk ◽  
M. Siddiqui ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Chen-Chih Chung ◽  
Lung Chan ◽  
Oluwaseun Adebayo Bamodu ◽  
Chien-Tai Hong ◽  
Hung-Wen Chiu

AbstractDespite the salient benefits of the intravenous tissue plasminogen activator (tPA), symptomatic intracerebral hemorrhage (sICH) remains a frequent complication and constitutes a major concern when treating acute ischemic stroke (AIS). This study explored the use of artificial neural network (ANN)-based models to predict sICH and 3-month mortality for patients with AIS receiving tPA. We developed ANN models based on evaluation of the predictive value of pre-treatment parameters associated with sICH and mortality in a cohort of 331 patients between 2009 and 2018. The ANN models were generated using eight clinical inputs and two outputs. The generalizability of the model was validated using fivefold cross-validation. The performance of each model was assessed according to the accuracy, precision, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). After adequate training, the ANN predictive model AUC for sICH was 0.941, with accuracy, sensitivity, and specificity of 91.0%, 85.7%, and 92.5%, respectively. The predictive model AUC for 3-month mortality was 0.976, with accuracy, sensitivity, and specificity of 95.2%, 94.4%, and 95.5%, respectively. The generated ANN-based models exhibited high predictive performance and reliability for predicting sICH and 3-month mortality after thrombolysis; thus, its clinical application to assist decision-making when administering tPA is envisaged.


Sign in / Sign up

Export Citation Format

Share Document